Page 9 - Graphite Bio News Today

Graphite Bio (NASDAQ:GRPH – Get Rating) and Cellectis (NASDAQ:CLLS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Graphite Bio and Cellectis’ […]

Graphite Bio (NASDAQ:GRPH – Get Rating) is one of 262 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Graphite Bio to related companies based on the strength of its institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Valuation and Earnings This […]

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the companys Board of Directors. Ms. Young has more...

BioPharma

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year.

Graphite Bio (NASDAQ:GRPH – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Graphite Bio Inc. is a clinical-stage, next-generation gene editing company focused on therapies to treat or cure serious diseases. Graphite Bio Inc. is […]

A bullish trade idea from Real Money's Bret Jensen on the XBI biotech ETF using covered calls...XBI

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) has been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The […]

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease - read this article along with other careers information, tips and advice on BioSpace

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,580,000 shares, a decline of 36.0% from the March 31st total of 4,030,000 shares. Approximately 10.7% of the company’s shares are sold short. Based on an average […]